A new paper on menopausal hormone therapy (MHT) and breast cancer risk has just been published in the Lancet. The International Menopause Society has released the following comment:
“Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.”
Collaborative Group on Hormonal Factors in Breast Cancer.
The Lancet 29th August 2019
The comment by the International Menopause Society in response to this publication is available here.
Current president of the International Menopause Society is Professor Susan Davis, Past-President of the AMS.